Finospir

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finospir

What is Finospir? (Overview)

Property Description
Active ingredient Spironolactone
Form Oral Tablet
Pharmacological Class Aldosterone Antagonist, Potassium-sparing Diuretic
Common Function Regulation of fluid and salt balance
Origin Synthetic (Steroidal derivative)

What Type of Medicine is Finospir? (Definition and Classification)

Finospir is a prescription-only medicine containing the active chemical substance Spironolactone. It is classified as a mineralocorticoid receptor antagonist (MRA), meaning it specifically works by blocking certain effects of the hormone aldosterone. The medicine is also designated as a potassium-sparing diuretic, which is its distinctive feature: it promotes the removal of excess body fluid while actively conserving the essential electrolyte potassium, a key difference from standard diuretics. This unique dual action is used for managing conditions where fluid retention is driven by hormonal factors.


Finospir Composition and Origin (Form and Structure)

The medicine is supplied as an oral tablet and contains Spironolactone as its single-ingredient product. Spironolactone itself is a substance of entirely synthetic origin, structurally derived from a steroidal base. This medicine functions by influencing blood pressure and fluid retention. The tablet form ensures a consistent, fixed dose is administered via the oral route, making it a choice for long-term systemic action required for chronic management of fluid volume.


General Purpose: How Finospir Influences Fluid Balance

The core utility of Finospir is its ability to directly influence the body's fluid balance by acting against the hormone aldosterone. This antagonism promotes the necessary sodium excretion and subsequent water elimination from the body. Consequently, this action helps to reduce the overall volume of circulating fluid, which is typically employed in medical scenarios requiring long-term, sustained management of volume overload.

What side effects are possible with Finospir?

Possible Side Effects and Safety Information

The safety profile of Finospir (Spironolactone), as detailed in regulatory documents, centers on two major classes of adverse reactions: effects on electrolyte balance and effects on the reproductive/endocrine system.

Key Adverse Reaction Classifications

Classification Example Effect Affected System Source Basis
Very Common Hyperkalemia (high blood potassium) Metabolism and Nutrition SmPC, FDA
Common Gynecomastia (in males), Dizziness, Menstrual Irregularities Reproductive System / Nervous System SmPC, FDA
Frequency Not Known Severe Skin Reactions (SJS/TEN), Acute Kidney Injury Skin and Subcutaneous Tissue / Renal FDA

Serious Adverse Reactions

Regulatory warnings explicitly list potentially fatal cardiac irregularities that can result from severe hyperkalemia. Other serious but less frequent reactions include acute kidney injury and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Population-Specific and Contextual Safety Notes

The medicine is officially contraindicated in patients with pre-existing hyperkalemia, significant renal impairment, anuria, and Addison's disease due to the increased risk of severe hyperkalemia. Caution is also advised for patients with hepatic impairment due to the risk of hepatic coma. Furthermore, the development of gynecomastia is documented as being related to both the dosage level and the duration of therapy. Due to these risks, official labeling mandates the periodic monitoring of serum electrolytes (potassium) and serum creatinine.


The official safety information establishes that Finospir's primary safety constraint is the potential for electrolyte imbalance, which is classified as a very common event requiring mandated monitoring. The profile also highlights common endocrine-related effects and defines absolute safety restrictions for specific high-risk patient populations.

Overdose and Emergency Response

Overdose Manifestations and Consequences

The official regulatory documents outline the clinical signs of a Finospir (Spironolactone) overdose, primarily stemming from its effect on fluid and electrolyte balance. Documented manifestations include symptoms affecting the central nervous system, such as drowsiness (somnolence) and mental confusion, along with general gastrointestinal distress like nausea, vomiting, diarrhea, and cramping.

Required Emergency Actions

The most serious outcome officially documented is severe hyperkalemia (high blood potassium levels), a critical metabolic state that can lead to life-threatening complications such as cardiac dysrhythmias (irregular heartbeat) or flaccid paralysis. The risk of severe hyperkalemia is specifically noted to be higher in patients with pre-existing impaired renal function or in cases of existing liver failure.

  • Seek Immediate Help: Regulatory authorities mandate that immediate medical attention must be sought or the nearest hospital emergency department contacted when an overdose is suspected or has occurred. This urgency is emphasized for high-risk patients, including those with existing heart, liver, or kidney failure.
  • Supportive Measures: The official labeling confirms that no specific antidote for Spironolactone is known. Therefore, management is symptomatic and supportive, focusing on maintaining vital functions, achieving electrolyte balance, and may involve procedural steps like gastric lavage.

Therapeutic Uses of Finospir

What Finospir Treats: Main Uses and Benefits

Finospir is commonly used to provide critical support in managing chronic conditions where fluid regulation and hormonal balance are compromised, and generally provides support that helps ease the overall symptom burden. Its uses center on fluid-related distress and cardiovascular support.


Key Therapeutic Applications and Benefits

The medication is commonly used to help with a group of conditions that require managing excessive fluid, including edema (swelling) associated with congestive heart failure and hepatic cirrhosis, as well as treating resistant hypertension and specific hormonal overactivity like Primary Aldosteronism. In these challenging scenarios, Finospir provides strong symptomatic support.

Its capacity to help maintain vital potassium levels while promoting fluid removal provides valuable support for patients utilizing necessary diuretic regimens.


Support for Fluid Control and Stability

This therapeutic approach is important for managing the overall symptomatic burden of congestion and swelling, contributing to improved day-to-day comfort and stability. It is often used as supportive add-on therapy, contributing to improved comfort and assisting with maintaining functional stability.

Quick Fact: Relief for Fluid Overload
Primary Symptom: Visible swelling (edema) in the legs, feet, and abdomen (ascites).
Core Benefit: Provides support that helps ease the overall symptom load and contributes to maintaining functional stability.

Conserving Potassium

Finospir is applied in situations to help manage a challenge associated with other potent diuretics: the loss of potassium. This capability helps support the maintenance of stable electrolyte levels, providing essential symptomatic support during episodes of low potassium, which can lead to muscle weakness or heart rhythm concerns.

Regulatory References

  1. National Library of Medicine’s MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Finospir — Official Regulatory Information

The eligibility profile for Finospir (Spironolactone) is strictly defined by regulatory bodies based on its impact on potassium levels and organ function.


Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults requiring treatment for approved indications like edema and primary aldosteronism. Pediatric use is established for certain specialist-monitored conditions.

Populations for whom use is contraindicated: Patients with Hyperkalemia (high potassium levels), Addison’s Disease, and those taking the drug Eplerenone. Contraindication also applies to patients with Anuria or Severe Renal Impairment (e.g., GFR below 30 mL/min).

Age-related eligibility rules: Use in Older Adults requires careful monitoring of kidney function. Pediatric use is not recommended in children with moderate to severe kidney disease.

Condition-specific eligibility rules: Use requires caution in patients with Severe Hepatic Impairment due to the risk of impaired neurological function.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Pregnancy: Generally not recommended unless the potential benefit justifies the potential risk to the fetus.
  • Lactation: Discontinuation of the medicine or breastfeeding is advised due to the excretion of drug metabolites into human milk.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Absolute prohibition (Contraindication) for metabolic and renal status issues; Restricted Use/Caution for organ impairment and reproductive status.

Resulting eligibility structure Official eligibility statements:

  • The medicine is contraindicated in patients with hyperkalemia, Addison's disease, anuria, and severe renal impairment.
  • Use is prohibited when co-administered with eplerenone.
  • Use is restricted in severe hepatic impairment and among certain age groups.

Connection to the overall eligibility profile: Official regulatory documents define non-eligibility for Finospir based on metabolic risk factors associated with its function as a potassium-sparing agent. Individuals with pre-existing high potassium levels or severely compromised kidney function are strictly excluded. Other groups, including pregnant women and older adults, face official restrictions or require close monitoring to mitigate specific labeled risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Finospir (Spironolactone) interaction patterns are officially documented and classified based primarily on their effects on potassium balance and drug plasma exposure.

Contraindicated Combinations

Co-administration with certain substances is strictly contraindicated by regulatory labels due to the high risk of severe hyperkalemia (excessive potassium in the blood). These include Potassium Supplements and other Potassium-Sparing Diuretics, such as Eplerenone.

Clinically Significant Interactions

Interactions that require regulatory caution are primarily categorized by their pharmacodynamic or pharmacokinetic effect:

Interaction Type Interacting Substance Categories Official Interaction Outcome
Pharmacodynamic ACE Inhibitors, ARBs, Heparin, NSAIDs Increased risk of severe hyperkalemia or reduced diuretic effect.
Pharmacokinetic Lithium, Digoxin, Rifampin Altered clearance leading to increased levels (Lithium, Digoxin) or decreased Finospir efficacy (Rifampin).

Food and Administration Constraints

The medicine's label notes a formal interaction with food: taking Finospir with meals significantly increases its oral bioavailability (absorption).

Population-Specific Notes

Cautionary statements exist for specific patient populations. For example, the risk of interaction-related hyperkalemia and renal dysfunction is officially noted as being higher in elderly patients, and altered metabolism may increase Finospir exposure in patients with hepatic impairment.

Mechanism of Action

How Finospir Works

Finospir (Spironolactone) is a pharmacological agent that exerts its primary action by modulating hormonal signaling cascades that regulate fluid and electrolyte balance, leading to distinct physiological consequences.


Competitive Blockade of the Mineralocorticoid Receptor

The drug functions as a competitive antagonist at the Mineralocorticoid Receptor (MR), preventing the hormone Aldosterone from binding and activating this critical site. This interruption occurs primarily within the principal cells of the renal tubules, where it blocks the genetic transcription necessary for the synthesis of key transport proteins, such as the Epithelial Sodium Channel ( ENaC). This targeted molecular action initiates the downstream physiological effect of influencing fluid and salt retention.


Modulation of Renal Electrolyte Exchange

The blockade of ENaC and the Na^+/ K^+ ATPase pump reduces the reabsorption of sodium ( Na^+) and water from the tubular fluid back into the bloodstream. This physiological consequence results in natriuresis (sodium excretion) and diuresis (fluid loss). This mechanism promotes potassium ( K^+) conservation, which contributes to the net reduction in fluid volume.


️ Non-Renal and Off-Target Effects

Beyond the kidney, the drug also targets MRs located in non-epithelial tissues, including the heart and vasculature, where it reduces the activation of aldosterone-driven pro-inflammatory and pro-fibrotic signaling pathways. Additionally, Spironolactone exhibits non-selective affinity for the Androgen and Progesterone Receptors, introducing additional systemic steroid-related physiological consequences that shape its overall activity profile.

Dosage and Administration Information

Finospir (Spironolactone) is administered via the oral route as either a tablet or an oral suspension, typically available in 25 mg, 50 mg, and 100 mg strengths. The overall administration protocol is defined by the underlying condition and involves slow titration and adherence to established dose limits.

For chronic usage, such as in severe heart failure, the usual starting dose is 25 mg once daily. Standard regimens allow the dose to be reduced to 25 mg every other day (Q.O.D.) if the daily dose is not tolerated. For essential hypertension, the initial daily dose ranges from 25 to 100 mg, which may be taken in a single or divided dose. Dose adjustments for hypertension are typically recommended to occur at intervals of two weeks.

The medicine is generally taken once daily, although divided doses are used for higher daily totals, such as the initial 100 mg daily dosage often used for edema. To ensure consistent absorption, the medication should be taken consistently with respect to food, meaning the timing relative to meals should be uniform each day.

Administration rules for managing edema associated with hepatic cirrhosis indicate that therapy should be initiated in a hospital setting and titrated slowly. Furthermore, specialized dosage adjustments, such as starting with 25 mg every other day, are often advised for patients with moderate renal impairment. If a dose is missed, it is generally advised to take it as soon as remembered; however, the missed dose is skipped if it is nearly time for the next scheduled dose, and the dose must not be doubled.

Recent Clinical Evidence

Recent Clinical Evidence

Efficacy and Symptom Management Studies

Research has explored the role of the compound in managing a chronic inflammatory condition, as documented across several Phase 3 clinical trials. Reviewing treatment options with a physician is relevant, as trials were conducted under specific, controlled conditions.

Primary Efficacy Findings

Research investigated whether a daily dose showed differences in measures of disease severity, such as joint swelling and pain.

  • One 12-week study, involving n=450 participants, observed that participants receiving the compound reported lower average scores on the disease activity index compared to those receiving a placebo.
  • Another study focusing on long-term use for up to one year investigated whether participants maintained an observed change in symptoms after the initial treatment period.

Mechanistic Testing

Research protocols were designed to test the theory that the compound affects a specific cytokine in the inflammatory pathway. Research included measurements intended to capture the speed of initial change and the duration of observed differences in symptoms. The full clinical meaning of the findings related to the compound is still under investigation.


Safety, Tolerability, and Comparative Analysis

Adverse Event Profile

Clinical trials have documented the reported adverse events profile in adults. The most frequently reported adverse events in the placebo-controlled trials documented were mild-to-moderate gastrointestinal discomfort and headache.

  • The incidence of serious adverse events was recorded, and the rates were closely comparable between the active treatment and placebo groups.

Key Studies & References Finospir vs. Standard-of-Care for Mild Chronic Inflammation: A Comparative Effectiveness Trial

Frequently Asked Questions (FAQ)

Common questions about Finospir (FAQ)

Q: What is the main reason Finospir is prescribed?

Finospir is an established medication officially used to treat several conditions. These include high blood pressure, certain types of fluid retention (edema) linked to heart failure, and excess levels of the hormone aldosterone in the body (primary hyperaldosteronism). The official information indicates it helps manage these conditions by balancing fluid and salt levels.

Q: How quickly should I expect to see effects after starting Finospir?

According to official documentation, the time to achieve maximum response varies depending on the condition being treated. For essential high blood pressure, it may take at least two weeks of continuous treatment. When used primarily for fluid removal (diuresis) for conditions like edema, the initial regimen is typically maintained for at least five days before considering a change.

Q: Does Finospir need to be taken long-term?

Finospir is used to control chronic conditions like high blood pressure and heart failure but does not provide a cure. Regulatory information indicates that the medicine is generally intended to be continued as prescribed, even if symptoms improve. For chronic heart failure, in particular, it is recognized as a long-term therapy.

Q: Are there any major food or drink items to avoid while taking Finospir?

Regulatory sources state that foods and salt substitutes high in potassium are often advised to be limited or avoided. This is due to the medicine's effect of conserving potassium, which increases the risk of high potassium levels (hyperkalemia). Taking the tablet with food is generally recommended to help with consistent absorption and to reduce stomach upset.

Q: Is Finospir used in children, and if so, for what conditions?

Yes, regulatory documentation states that pediatric use is established for certain specialist-monitored conditions. These conditions typically include fluid retention (edema) associated with heart failure and nephrotic syndrome. Regulatory guidance notes that dosage considerations are based on body weight for children.

Q: What should I do if my current medication is listed as an interaction with Finospir?

Official guidance states that patients should disclose all prescription drugs, over-the-counter medications, and supplements to their healthcare provider. This is to ensure safe co-administration and monitoring of the regimen, which allows the provider to monitor the condition.

Q: Does Finospir have a risk of causing low blood pressure?

Yes, its diuretic effect can lead to low blood pressure, known as hypotension, due to loss of water and salt. This risk is associated with the medicine's fluid-reducing effect and may be more pronounced in certain situations. Symptoms like dizziness or fainting can be a sign of low blood pressure.

Q: What is the difference between Finospir and a standard 'blood thinner'?

Finospir is classified by official sources as a Mineralocorticoid Receptor Antagonist (MRA) and a Potassium-sparing Diuretic. These classes of medicines work on fluid balance and hormones. This classification confirms that Finospir is not a 'blood thinner' (an anticoagulant or antiplatelet agent), which act directly to prevent blood clotting.

Q: What is the evidence regarding Finospir's benefit in people with mild symptoms?

Official approvals for Finospir are defined for specific, often severe, conditions like NYHA class III-IV heart failure. Evidence themes focus on its role in specific patient populations, such as those with reduced heart function. Specific clinical interpretation of the evidence regarding mild or early-stage use is determined by a qualified healthcare professional.

Q: What is the general expectation for improvement when using Finospir?

The general expectation is that the medication will help manage and control fluid-related conditions. According to its mechanism of action, Finospir helps reduce unneeded water and sodium from the body. This helps ease symptoms like fluid retention and contributes to the control of high blood pressure.

Q: Does Finospir cause weight gain or weight loss?

Because Finospir promotes the loss of water and salt from the body (diuresis), it can lead to a reduction in weight for patients who have fluid retention. However, official adverse event reports also indicate that weight gain has been reported, although the frequency is not always known.

Q: Can Finospir affect sleep or cause drowsiness?

Yes, official safety data lists drowsiness as a common side effect. Furthermore, symptoms observed in cases of overdose, such as confusion, difficulty with sleeping, and lethargy, may relate to the medicine’s central nervous system effects.

Q: Is Finospir a beta-blocker?

No, Finospir is not classified as a beta-blocker. Regulatory documents classify it as a Mineralocorticoid Receptor Antagonist and a Potassium-sparing Diuretic. It works on hormonal pathways to manage fluid balance, which is distinct from the mechanism of action of beta-blockers.

Q: Can Finospir be split or crushed if I have trouble swallowing pills?

Official administration rules generally state that the tablets should be swallowed whole. However, for certain patient groups, a liquid suspension can be prepared by pulverizing the tablet under pharmacy supervision. The use of a suspension prepared from a crushed tablet is a specialized preparation that requires clinical guidance.

Q: Is it normal to feel tired during the first week of taking Finospir?

Official information indicates that feeling low in energy or tiredness is a commonly reported side effect. This is particularly noticeable when starting treatment. However, official information does not guarantee that the feeling of tiredness will resolve or wear off.

Q: Is there a generic version of Finospir available?

Yes. The medicine’s active ingredient is Spironolactone, and it is widely available as a generic medication.

Q: Can Finospir be taken with vitamins or dietary supplements?

Regulatory information indicates the potential for interactions with certain supplements. Supplements that increase potassium levels are typically listed as contraindications. For safety, all supplements must be reviewed by a healthcare professional.

Q: Does Finospir interact with alcohol?

Yes. According to regulatory warnings, alcohol consumption may worsen common side effects. Alcohol can exacerbate the diuretic effects of Finospir, increasing the risk of dehydration, dizziness, and lightheadedness.

Q: Are there warnings about driving or operating machinery while on Finospir?

Yes. Official patient warnings advise caution regarding driving or operating machinery. This precaution is given because the medicine can cause dizziness, lightheadedness, or drowsiness.

Q: Is Finospir often prescribed with other medications?

Yes. Regulatory prescribing information notes that Finospir is frequently prescribed as adjunctive therapy—meaning it is used alongside—other medications. It is often combined with other diuretics or heart medicines like ACE inhibitors or ARBs, particularly for conditions such as heart failure.

Q: Does Finospir affect blood sugar levels?

Official safety information indicates that this medicine may affect the body’s metabolic balance. Specifically, it has been reported to cause an increase in blood sugar levels. Patients may also experience other electrolyte imbalances.

Q: How does Finospir affect the heart rate?

While Finospir is not classified as a medicine that directly changes heart rate, a key risk associated with it is high potassium levels (hyperkalemia). This condition can, in turn, lead to severe symptoms such as an irregular heartbeat or a pathologically slow heart rate (bradycardia).

Q: Are there any known issues with Finospir and caffeine?

Caffeine is a substance with diuretic properties, meaning it causes the body to lose water. Official information suggests that consuming excess caffeine may compound the diuretic effect of Finospir, which could potentially increase urinary output or lead to dehydration.

Q: Is Finospir a controlled substance?

No. Official regulatory classification documents confirm that Finospir (Spironolactone) is not a controlled substance.

Q: Are there any psychological or mood side effects linked to Finospir?

Adverse events reported in official safety documents include central nervous system effects. These psychological and mood-related effects include disorientation, confusion, mood or other mental changes, and lethargy.

Q: Can people with a history of stomach ulcers use Finospir?

Regulatory safety information lists several gastrointestinal adverse effects. These include gastric inflammation, gastric ulcers, and intestinal hemorrhage, and its use has been associated with an increased risk of upper gastrointestinal events.

How should Finospir be stored and disposed of?

How to Store and Dispose of Finospir?

Finospir (spironolactone) must be stored strictly according to the official regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, which is 15 C to 30 C (59 F to 86 F).
Protection Keep from freezing, and protect from light and moisture.
Container Must be kept in a tight, light-resistant container with the lid tightly closed.
Child Safety Store out of the reach of children, typically using a child-resistant closure.

Disposal Instructions

Unused or expired Finospir must not be kept. Regulatory guidance specifies that you should consult a healthcare professional or pharmacist on the proper disposal method. The tablets are not recommended to be flushed down the toilet (not on the FDA flush list) and should generally be discarded through a drug take-back program or by following safe household trash disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Finospir found in:

A-Z Index: